Drug manufacturing has historically been a batch process — make a lot, test it, move it to the next step, repeat — which is slow, inventory-heavy and test-at-the-end. Regulators now actively encourage continuous manufacturing, where materials flow steadily through integrated unit operations, with quality verified in real time.
Working principle
Reaction, separation, crystallisation, drying and even tableting are linked into one continuous train. Process Analytical Technology (PAT) — inline spectroscopy and sensors — monitors quality continuously, and a control system adjusts conditions on the fly, embodying Quality-by-Design (QbD). Steady-state operation means consistent conditions and product, while small equipment reduces footprint and waste. Scale-up is largely a matter of running longer, not building bigger vessels.
| Aspect | Batch | Continuous |
|---|---|---|
| Quality testing | End-of-batch | Real-time (PAT) |
| Footprint | Large | Compact |
| Scale-up | New larger vessels | Run longer / number-up |
| Agility | Slow changeover | Fast, on-demand |
| Waste | Higher | Lower |
Why it mattersContinuous manufacturing supports agile, on-demand medicine production and tighter quality — the FDA and EMA explicitly endorse it. The barriers are process understanding, control, and regulatory familiarity.
Applications
- End-to-end small-molecule API and tablet production
- On-demand and distributed manufacture of essential medicines
- Robust production of unstable or hazardous intermediates
References & further reading
- Lee et al., “Modernizing Pharmaceutical Manufacturing: from Batch to Continuous Production,” J. Pharm. Innov., 2015.
- Adamo et al., “On-demand continuous-flow production of pharmaceuticals in a compact, reconfigurable system,” Science, 2016.
- FDA, “Quality Considerations for Continuous Manufacturing — Guidance for Industry,” 2019.